These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 26297500)

  • 1. Reduction in peripheral vascular resistance predicts improvement in insulin clearance following weight loss.
    Straznicky NE; Grima MT; Sari CI; Lambert EA; Phillips SE; Eikelis N; Kobayashi D; Hering D; Mariani JA; Dixon JB; Nestel PJ; Karapanagiotidis S; Schlaich MP; Lambert GW
    Cardiovasc Diabetol; 2015 Aug; 14():113. PubMed ID: 26297500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased fiber intake predicts the decrease in 2nd phase glucose-induced hyperinsulinemia following a hypocaloric diet in obese subjects.
    Provost V; Lamantia V; Bissonnette S; Cyr Y; Faraj M
    Nutr Metab Cardiovasc Dis; 2019 May; 29(5):504-512. PubMed ID: 30948306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arterial norepinephrine concentration is inversely and independently associated with insulin clearance in obese individuals with metabolic syndrome.
    Straznicky NE; Grima MT; Lambert EA; Sari CI; Eikelis N; Nestel PJ; Phillips SE; Hering D; Karapanagiotidis S; Dixon JB; Schlaich MP; Lambert GW
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1544-50. PubMed ID: 25590214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pioglitazone treatment enhances the sympathetic nervous system response to oral carbohydrate load in obese individuals with metabolic syndrome.
    Straznicky NE; Grima MT; Sari CI; Eikelis N; Lambert GW; Nestel PJ; Richards K; Dixon JB; Schlaich MP; Lambert EA
    Metabolism; 2015 Jul; 64(7):797-803. PubMed ID: 25827058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial of the effects of pioglitazone treatment on sympathetic nervous system activity and cardiovascular function in obese subjects with metabolic syndrome.
    Straznicky NE; Grima MT; Sari CI; Eikelis N; Lambert GW; Nestel PJ; Karapanagiotidis S; Wong C; Richards K; Marusic P; Dixon JB; Schlaich MP; Lambert EA
    J Clin Endocrinol Metab; 2014 Sep; 99(9):E1701-7. PubMed ID: 24937541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline sympathetic nervous system activity predicts dietary weight loss in obese metabolic syndrome subjects.
    Straznicky NE; Eikelis N; Nestel PJ; Dixon JB; Dawood T; Grima MT; Sari CI; Schlaich MP; Esler MD; Tilbrook AJ; Lambert GW; Lambert EA
    J Clin Endocrinol Metab; 2012 Feb; 97(2):605-13. PubMed ID: 22090279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome.
    Straznicky NE; Lambert EA; Lambert GW; Masuo K; Esler MD; Nestel PJ
    J Clin Endocrinol Metab; 2005 Nov; 90(11):5998-6005. PubMed ID: 16091482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relation of glucose metabolism to left ventricular mass and function and sympathetic nervous system activity in obese subjects with metabolic syndrome.
    Straznicky NE; Grima MT; Sari CI; Karapanagiotidis S; Wong C; Eikelis N; Richards KL; Lee G; Nestel PJ; Dixon JB; Lambert GW; Schlaich MP; Lambert EA
    J Clin Endocrinol Metab; 2013 Feb; 98(2):E227-37. PubMed ID: 23271752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of weight loss versus weight loss maintenance on sympathetic nervous system activity and metabolic syndrome components.
    Straznicky NE; Grima MT; Eikelis N; Nestel PJ; Dawood T; Schlaich MP; Chopra R; Masuo K; Esler MD; Sari CI; Lambert GW; Lambert EA
    J Clin Endocrinol Metab; 2011 Mar; 96(3):E503-8. PubMed ID: 21177786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparable Attenuation of Sympathetic Nervous System Activity in Obese Subjects with Normal Glucose Tolerance, Impaired Glucose Tolerance, and Treatment Naïve Type 2 Diabetes following Equivalent Weight Loss.
    Straznicky NE; Grima MT; Sari CI; Lambert EA; Phillips SE; Eikelis N; Mariani JA; Kobayashi D; Hering D; Dixon JB; Lambert GW
    Front Physiol; 2016; 7():516. PubMed ID: 27857694
    [No Abstract]   [Full Text] [Related]  

  • 11. Blunted sympathetic neural response to oral glucose in obese subjects with the insulin-resistant metabolic syndrome.
    Straznicky NE; Lambert GW; Masuo K; Dawood T; Eikelis N; Nestel PJ; McGrane MT; Mariani JA; Socratous F; Chopra R; Esler MD; Schlaich MP; Lambert EA
    Am J Clin Nutr; 2009 Jan; 89(1):27-36. PubMed ID: 19056585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement in insulin sensitivity by weight loss does not affect hyperinsulinemia-mediated reduction in total and high molecular weight adiponectin: a MONET study.
    Drapeau S; Doucet E; Rabasa-Lhoret R; Brochu M; Prud'homme D; Imbeault P
    Appl Physiol Nutr Metab; 2011 Apr; 36(2):191-200. PubMed ID: 21609280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Branched-chain amino acid catabolism rather than amino acids plasma concentrations is associated with diet-induced changes in insulin resistance in overweight to obese individuals.
    Haufe S; Engeli S; Kaminski J; Witt H; Rein D; Kamlage B; Utz W; Fuhrmann JC; Haas V; Mähler A; Schulz-Menger J; Luft FC; Boschmann M; Jordan J
    Nutr Metab Cardiovasc Dis; 2017 Oct; 27(10):858-864. PubMed ID: 28958691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of weight loss in massive obesity on insulin and C-peptide dynamics: sequential changes in insulin production, clearance, and sensitivity.
    Jimenez J; Zuniga-Guajardo S; Zinman B; Angel A
    J Clin Endocrinol Metab; 1987 Apr; 64(4):661-8. PubMed ID: 3546350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ANP system activity predicts variability of fat mass reduction and insulin sensitivity during weight loss.
    Brachs M; Wiegand S; Leupelt V; Ernert A; Kintscher U; Jumpertz von Schwarzenberg R; Decker AM; Bobbert T; Hübner N; Chen W; Krude H; Spranger J; Mai K
    Metabolism; 2016 Jun; 65(6):935-43. PubMed ID: 27173472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of hyperinsulinemia and insulin resistance during the early stage of weight gain.
    Erdmann J; Kallabis B; Oppel U; Sypchenko O; Wagenpfeil S; Schusdziarra V
    Am J Physiol Endocrinol Metab; 2008 Mar; 294(3):E568-75. PubMed ID: 18171910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of insulin on vascular tone and sympathetic nervous system in NIDDM.
    Tack CJ; Smits P; Willemsen JJ; Lenders JW; Thien T; Lutterman JA
    Diabetes; 1996 Jan; 45(1):15-22. PubMed ID: 8522054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation between obesity and insulin resistance in the association with C-reactive protein.
    McLaughlin T; Abbasi F; Lamendola C; Liang L; Reaven G; Schaaf P; Reaven P
    Circulation; 2002 Dec; 106(23):2908-12. PubMed ID: 12460870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of body weight, hyperinsulinemia and oral glucose load on serum C-peptide/insulin molar ratio.
    Okada N; Kobayashi M; Ohtsuka H; Shigematsu S; Nagasawa Y; Komatsu M; Aizawa T; Yamada T
    Horm Metab Res; 1992 Sep; 24(9):429-33. PubMed ID: 1427614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroadrenergic dysfunction along the diabetes continuum: a comparative study in obese metabolic syndrome subjects.
    Straznicky NE; Grima MT; Sari CI; Eikelis N; Lambert EA; Nestel PJ; Esler MD; Dixon JB; Chopra R; Tilbrook AJ; Schlaich MP; Lambert GW
    Diabetes; 2012 Oct; 61(10):2506-16. PubMed ID: 22664956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.